Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A…
この記事を読む
記事一覧 27ページ
この記事を読む
免疫療法とサルコペニア～存在より減少するかどうかが大切
Cachexia – sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients rece…
この記事を読む
PD-L1陽性例でもペムブロリズマブの脳転移への効果は2割程度
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from …
この記事を読む
ROS1陽性は血栓塞栓症のハイリスク群
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. A…
この記事を読む
標準治療後の小細胞肺癌に対するペムブロリズマブ、期待は持てそうだが…
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From th…
この記事を読む
循環腫瘍DNAが早く消失してもアウトカムは変わらない
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epide…
この記事を読む
KEYNOTE-189 up date
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metast…
この記事を読む
根治治療後のフォローはどうすべきか？
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Schneider BJ J Clin Oncol. 2020 Mar 1…
この記事を読む
クライオバイオプシーはEGFR遺伝子変異検出に有利？
Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer. Haentschel M et al. Lung Cancer. 2020 Mar;14…
この記事を読む
TKI+ベバシズマブでT790Mが減る？
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with…